New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For BMY;PFE;DUF;CG;HLF;CALM From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
<< 1 | 2 | all recent news | >>
March 27, 2015
07:25 EDTPFETeva appears to be weighing transformative deal, says Bernstein
After attending Teva's (TEVA) meeting with investors, Bernstein thinks that the company is considering making a 'transformative' acquisition, although it believes that such a deal may not be imminent. The firm sees Mylan ((MYL) and the generic units of Actavis (ACT), Pfizer (PFE), and possibly Valeant (VRX) as the four logical candidates. It says that Teva can pay $81 per share for Mylan, and that a takeover of Mylan would raise Teva's EPS to about $6.50 in 2017 and $7 in 2018. Bernstein raised its price target on Teva to $69 from $60 and keeps an Outperform rating on the shares.
March 26, 2015
07:30 EDTBMY, PFEDeutsche Bank to hold a conference
Pharma One-on-One Day is being held in Denver, Colorado on March 26.
March 24, 2015
08:02 EDTBMYBristol-Myers acquires exclusive license from Novo Nordisk for research program
Subscribe for More Information
07:45 EDTPFEFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
07:27 EDTCGTelsey Advisory to hold a conference
2015 Consumer Conference is being held in New York on March 24-25.
07:07 EDTHLFHerbalife plans PR campaign to hit back at Ackman, CNBC reports
Subscribe for More Information
March 23, 2015
11:26 EDTHLFHerbalife rallies, retraces, levels to watch
The shares hit an intraday high at $48.55 and have since turned lower. At the last price of $46.04, support is at $45.11 and then at $44.11, a prior pivot high. Resistance is at $46.24.
11:09 EDTPFEPfizer hits best level in over decade after Jefferies adds to list of best ideas
The shares of Pfizer (PFE) are rising after an analyst wrote that the company's shares are poised to rise significantly over the next one to two years. Additionally, the company announced that it would resume developing its painkiller, tanezumab, in partnership with Eli Lilly (LLY). ANALYST OUTLOOK: Pfizer's breast cancer drug for postmenopausal women, Ibrance, has had one of the best launches of any oncology drug ever, Jefferies analyst Jeffrey Holdford wrote in a note to investors today. A survey of U.S. oncologists conducted by the firm shows that the doctors expect the drug to be used on about 50% of patients needing first line hormonal therapy within one year, while the drug will be used as an off-label treatment in all lines of therapy, the analyst wrote. The drug will generate revenue of $5.5B in 2020, versus the consensus outlook of $3.3B, Holford estimated. Meanwhile, the drug maker's Global Established Pharmaceutical, or GEP, business' revenue and profits should top consensus estimates by14% by 2018, according to the analyst. Pfizer could generate value through accretive M&A activity and by separating the GEP unit by 2017, Holdford stated. He raised his price target on the name to $45 from $42, kept a buy rating on the shares, and added the stock to the firm's Franchise Picks list, which encompasses its best ideas. WHAT'S NOTABLE: Pfizer announced that, in partnership with Eli Lilly, it would resume its Phase 3 clinical program for tanezumab. The announcement was made after the FDA removed a partial clinical hold on the drug, Pfizer noted. As a result of its decision, Pfizer expects to receive a $200M payment, in accordance with the companies' agreement, Pfizer stated. PRICE ACTION: In mid-morning trading, Pfizer climbed 2.4% to $35.08. The stock has not traded at a price per share this high since 2004.
11:01 EDTPFEPfizer rallies to fresh 52-week high, levels to watch
Shares are up over 2.8% at time of writing to $35.14, just below the new 52-week high at $35.26 which is now initial resistance. Next resistance above is at $35.89 and then at $36.63. Support is at $34.89.
10:53 EDTHLFHerbalife continues recent strength with 10% jump
Shares of multi-level marketing company Herbalife (HLF) were up about 10% in morning trading after being up as much as 15% to $48.55 earlier this morning. On March 16, a judge in the U.S. District Court for the Central District of California granted Herbalife its motion to dismiss a class action complaint brought on behalf of shareholders who allege that the company and its executives violated federal securities laws by misrepresenting the "nature, scope and legality" of the company's business and operations. On March 20, Pershing Square, which noted that Bill Ackman and the firm were not parties to the Awad case decided the prior week, said the courtís decision "did not address in any way whether Herbalife is an illegal pyramid scheme, nor did the Court exonerate or bless Herbalifeís business practices." Since March 16, Herbalife shares are up about 29%.
10:14 EDTHLFHerbalife volatility elevated on sharp rally
Subscribe for More Information
10:09 EDTCGCarlyle doesn't see strong dollar discouraging long-term investors, Reuters says
Subscribe for More Information
09:37 EDTPFEActive equity options trading on open
Active equity options trading on open according to Track Data: AAPL AUY SLB PFE MCP CELG VRTX SHPG GILD LOGI TSLA TASR NFLX SCTY WFM
08:06 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Pfizer (PFE) and Eli Lilly and Company (LLY) announced that they are preparing to resume the Phase 3 clinical program for tanezumab. As a result, Pfizer expects to receive a $200M upfront payment from Lilly in accordance with their collaboration agreement. This announcement follows a decision by the U.S. FDA to lift the partial clinical hold on the tanezumab development program after a review of a robust body of nonclinical data characterizing the sympathetic nervous system response to tanezumab. The data were submitted to the FDA in February. In the prior clinical studies of more than 11,000 patients, tanezumab demonstrated clinically meaningful efficacy vs. placebo and other select commonly used pain medicines. A partial clinical hold has been in place for tanezumab and all other anti-nerve growth factor antibodies since December 2012 due to adverse changes in the sympathetic nervous system of mature animals. Studies in terminal cancer pain were allowed to proceed.
08:05 EDTPFEPfizer, Eli Lilly to resume Phase 3 chronic pain program for Tanezumab
Subscribe for More Information
07:36 EDTPFEPfizer should rise 'significantly' over next two years, says Jefferies
Jefferies analyst Jeffrey Holford told investors this morning that he expects shares of Pfizer (PFE) to appreciate "significantly" over the next two years. A survey of U.S. oncologists indicated the company's Ibrance drug will be used in 50% of first line hormonal therapy within one year, with off-label use in all lines of therapy including adjuvant, Holford noted. He thinks peak sales of the drug could top $13B, which is well above consensus. In addition, the analyst views Pfizer's Global Established Pharmaceutical business as being underappreciated by the market. Potential value creating options for the pharmaceutical giant include spinning off its GEP unit by 2017 and accretive acquisitions, with possible takeover targets being Shire (SHPG), Actavis (ACT), AstraZeneca (AZN) and GlaxoSmithKline (GSK), in the eyes of Holford. He added the stock to the firm's Franchise Picks list, which encompasses its best ideas. He also raised his price target for Pfizer to $45 from $42. The stock closed Friday up 10c to $34.25.
06:57 EDTCGSilver Lake weighs GBP2B bid for Tesco's Dunnhumby, Sunday Times reports
Subscribe for More Information
March 20, 2015
15:45 EDTHLFHerbalife breaks above top of recent range, levels to watch
Shares have broken out of the top of the recent trading range at $40. This is bullish price behavior. At the current price of $40.79 next resistance is at $42. Support is at $40. It would be bearish for price if the stock resumes trading below the $40 area.
15:38 EDTHLFHerbalife volatility stays elevated on sharp rally
Subscribe for More Information
13:50 EDTHLFPershing Square corrects inaccurate press reports regarding Herbalife
Subscribe for More Information
13:03 EDTPFEPfizer says oral tofacitinib meets primary endpoint in Phase 3 trials
Subscribe for More Information
07:55 EDTPFE, BMYAstraZeneca seen as potential target again if oncology drugs lag, Bloomberg says
Subscribe for More Information
07:41 EDTPFEAmerican Academy of Dermatology to hold annual meeting
Subscribe for More Information
March 19, 2015
11:02 EDTHLFOptions with increasing implied volatility
Options with increasing implied volatility: HLF RAD NFLX HLSS NOW
11:00 EDTPFEPfizer participates in a conference call with Bernstein
Subscribe for More Information
March 18, 2015
17:09 EDTPFEPfizer CAPiTA published in New England Journal of Medicine
Subscribe for More Information
13:49 EDTHLFHerbalife says 'confident in strong fundamentals of business model'
Subscribe for More Information
09:23 EDTHLFOn The Fly: Pre-market Movers
Subscribe for More Information
08:02 EDTHLFHerbalife wins dismissal of class action 'pyramid scheme' lawsuit
On March 16, a judge in the U.S. District Court for the Central District of California granted Herbalife its motion to dismiss a class action complaint brought on behalf of shareholders who allege that the company and its executives violated federal securities laws by misrepresenting the "nature, scope and legality" of the company's business and operations. According to the plaintiffs, Herbalife and its executives, including CEO Michael Johnson, misrepresented Herbalife as a legitimate multi-level marketing company when it "is actually an illegal pyramid scheme." The court concluded that the suit's plaintiffs have not adequately pled loss causation, meaning that the court need not consider Herbalifeís alternative arguments, according to a court filing. Shares of Herbalife are up 3% in pre-market trading after the court dismissal was widely reported by Bloomberg last night.
07:13 EDTHLFHerbalife complaint letter signer subpoenaed, Hartford Courant reports
Subscribe for More Information
March 17, 2015
19:42 EDTHLFOn The Fly: After Hours Movers
Subscribe for More Information
18:27 EDTHLFHerbalife up over 5% following favorable court ruling in 'pyramid scheme' suit
Subscribe for More Information
18:07 EDTHLFHerbalife wins dismissal of 'pyramid scheme' lawsuit, Bloomberg says
10:26 EDTHLFOptions with increasing implied volatility
Subscribe for More Information
March 16, 2015
12:45 EDTCALMCal-Maine Foods management to meet with Sidoti
Subscribe for More Information
06:40 EDTPFEPCSK9 studies show potential improvement in heart health, WSJ says
Subscribe for More Information
05:50 EDTHLFStocks with implied volatility movement; FIG HLF
Subscribe for More Information
<< 1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use